154 related articles for article (PubMed ID: 21755276)
21. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
22. Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Leuk Res; 2020 Jun; 93():106318. PubMed ID: 32127177
[TBL] [Abstract][Full Text] [Related]
23. [Current and new therapeutic strategies in acute myeloid leukemia].
Naito K; Ohnishi K
Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
[TBL] [Abstract][Full Text] [Related]
24. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
26. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
[TBL] [Abstract][Full Text] [Related]
27. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
30. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
[TBL] [Abstract][Full Text] [Related]
31. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G
Ann Oncol; 2008 Jan; 19(1):128-34. PubMed ID: 17906298
[TBL] [Abstract][Full Text] [Related]
32. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
Higashi Y; Turzanski J; Pallis M; Russell NH
Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
34. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
35. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
36. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789
[TBL] [Abstract][Full Text] [Related]
37. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
Clavio M; Vignolo L; Albarello A; Varaldo R; Pierri I; Catania G; Balocco M; Michelis G; Miglino M; Manna A; Balleari E; Carella AM; Sessarego M; Van Lint MT; Bacigalupo A; Gobbi M
Br J Haematol; 2007 Jul; 138(2):186-95. PubMed ID: 17593025
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Ragon BK; Daver N; Garcia-Manero G; Ravandi F; Cortes J; Kadia T; Oran B; Ohanian M; Ferrajoli A; Pemmaraju N; Kantarjian HM; Borthakur G
Am J Hematol; 2017 Sep; 92(9):845-850. PubMed ID: 28494506
[TBL] [Abstract][Full Text] [Related]
39. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
[TBL] [Abstract][Full Text] [Related]
40. A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
Ashaye AO; Khankhel Z; Xu Y; Fahrbach K; Mokgokong R; Orme ME; Lang K; Cappelleri JC; Mamolo C
Future Oncol; 2019 Feb; 15(6):663-681. PubMed ID: 30450960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]